EntryPoint Capital LLC Acquires Shares of 25,168 AtriCure, Inc. $ATRC

Key Points

• EntryPoint Capital LLC acquired 25,168 shares of AtriCure, Inc. for approximately $812,000, making it the firm's 13th largest position in its portfolio.
• Institutional investors collectively own 99.11% of AtriCure's stock, with notable increases from firms like Canada Pension Plan Investment Board, which raised its holdings by 756.1% in the last quarter.
• AtriCure recently reported a quarterly earnings beat, with $136.14 million in revenue and an earnings per share of -$0.02, exceeding analysts' expectations.

EntryPoint Capital LLC purchased a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 25,168 shares of the medical device company's stock, valued at approximately $812,000. AtriCure makes up approximately 0.4% of EntryPoint Capital LLC's investment portfolio, making the stock its 13th biggest position. EntryPoint Capital LLC owned 0.05% of AtriCure as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of ATRC. First Horizon Advisors Inc. lifted its stake in AtriCure by 135.3% during the 1st quarter. First Horizon Advisors Inc. now owns 1,447 shares of the medical device company's stock valued at $47,000 after acquiring an additional 832 shares during the period. US Bancorp DE lifted its position in AtriCure by 98.1% during the first quarter. US Bancorp DE now owns 1,593 shares of the medical device company's stock valued at $51,000 after purchasing an additional 789 shares during the period. Johnson Financial Group Inc. lifted its position in AtriCure by 1,184.1% during the fourth quarter. Johnson Financial Group Inc. now owns 1,618 shares of the medical device company's stock valued at $49,000 after purchasing an additional 1,492 shares during the period. Heck Capital Advisors LLC purchased a new stake in AtriCure in the fourth quarter worth approximately $60,000. Finally, State of Wyoming grew its position in AtriCure by 21.9% in the 4th quarter. State of Wyoming now owns 2,481 shares of the medical device company's stock worth $76,000 after purchasing an additional 446 shares during the period. 99.11% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. BTIG Research set a $54.00 price target on AtriCure in a research note on Wednesday, July 30th. UBS Group dropped their target price on AtriCure from $60.00 to $58.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. JMP Securities restated a "market outperform" rating and set a $60.00 price target on shares of AtriCure in a research note on Wednesday, April 30th. Needham & Company LLC increased their price objective on shares of AtriCure from $44.00 to $45.00 and gave the stock a "buy" rating in a research note on Wednesday, July 30th. Finally, Wall Street Zen upgraded shares of AtriCure from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Nine equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $50.89.

AtriCure Stock Performance

Shares of NASDAQ:ATRC traded up $1.93 during mid-day trading on Friday, reaching $37.66. 525,425 shares of the company traded hands, compared to its average volume of 719,676. The company's 50 day moving average price is $33.05 and its 200-day moving average price is $33.88. The firm has a market cap of $1.87 billion, a PE ratio of -48.91 and a beta of 1.61. AtriCure, Inc. has a 52 week low of $24.48 and a 52 week high of $43.11. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.94 and a quick ratio of 2.83.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The medical device company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.13. The business had revenue of $136.14 million for the quarter, compared to the consensus estimate of $130.17 million. AtriCure had a negative net margin of 7.27% and a negative return on equity of 4.20%. The company's revenue for the quarter was up 17.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.17) earnings per share. AtriCure has set its FY 2025 guidance at -0.390--0.340 EPS. On average, equities analysts expect that AtriCure, Inc. will post -0.6 EPS for the current fiscal year.

Insider Buying and Selling at AtriCure

In related news, insider Vinayak Doraiswamy sold 2,500 shares of the business's stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $36.58, for a total value of $91,450.00. Following the transaction, the insider directly owned 71,872 shares of the company's stock, valued at approximately $2,629,077.76. The trade was a 3.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Regina E. Groves sold 2,452 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $36.82, for a total value of $90,282.64. Following the completion of the transaction, the director owned 33,715 shares of the company's stock, valued at $1,241,386.30. The trade was a 6.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,452 shares of company stock valued at $445,333 over the last ninety days. 3.50% of the stock is currently owned by company insiders.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.